XML 29 R14.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Information | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Segment Information | Segment Information We have four reportable business segments (Asia, Europe, North America and Latin America and Other) based primarily upon the geographic region where each segment operates, as well as the internal organization of our officers and their responsibilities. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy WorldWide® brands and sell similar products grouped into six principal categories: general health, immune, cardiovascular, digestive, personal care and weight management. The Latin America and Other segment includes our wholesale business in which we sell products to various locally-managed entities, independent of the Company, that we have granted distribution rights for the relevant market. The Company's chief operating decision maker ("CODM") is our chief executive officer. The CODM assesses the performance of each segment using operating income. The CODM reviews the performance of each segment using monthly internal reports which provide variance analysis of actual results by segment compared to budget, forecast and prior year. The CODM uses this information when making decisions about the allocation of operating resources to each segment. The CODM does not evaluate reportable segments using asset or liability information. Reportable business segment information for the three and nine months ended September 30, 2025 and 2024, is as follows (dollar amounts in thousands):
Three Months Ended September 30, 2025 |  | Asia |  | Europe |  | North America |  | Latin America and Other |  | Total
Net sales |  | $ | 64,725 |  |  | $ | 22,107 |  |  | $ | 36,224 |  |  | $ | 5,283 |  |  | $ | 128,339 |
Cost of sales |  | 13,906 |  |  | 6,464 |  |  | 12,043 |  |  | 1,877 |  |  |
Volume incentives |  | 21,524 |  |  | 8,726 |  |  | 7,383 |  |  | 1,715 |  |  |
Selling, general and administrative (1) |  | 16,177 |  |  | 4,599 |  |  | 9,009 |  |  | 1,416 |  |  |
Segment operating income |  | $ | 13,118 |  |  | $ | 2,318 |  |  | $ | 7,789 |  |  | $ | 275 |  |  | $ | 23,500 |
Unallocated corporate selling, general and administrative expense |  |  |  |  |  |  |  |  |  | (14,525) |
Operating income |  |  |  |  |  |  |  |  |  | 8,975 |
Interest and other income, net |  |  |  |  |  |  |  |  |  | 51 |
Interest expense |  |  |  |  |  |  |  |  |  | (26) |
Foreign exchange gains, net |  |  |  |  |  |  |  |  |  | 672 |
Income from operations before provision for income taxes |  |  |  |  |  |  |  |  |  | $ | 9,672 |
Three Months Ended September 30, 2024 |  | Asia |  | Europe |  | North America |  | Latin America and Other |  | Total
Net sales |  | $ | 55,293 |  |  | $ | 19,615 |  |  | $ | 33,631 |  |  | $ | 6,076 |  |  | $ | 114,615 |
Cost of sales |  | 13,357 |  |  | 6,698 |  |  | 10,818 |  |  | 1,983 |  |  |
Volume incentives |  | 18,895 |  |  | 7,676 |  |  | 7,152 |  |  | 1,798 |  |  |
Selling, general and administrative (1) |  | 12,689 |  |  | 4,535 |  |  | 8,218 |  |  | 1,604 |  |  |
Segment operating income |  | $ | 10,352 |  |  | $ | 706 |  |  | $ | 7,443 |  |  | $ | 691 |  |  | $ | 19,192 |
Unallocated corporate selling, general and administrative expense |  |  |  |  |  |  |  |  |  | (13,908) |
Operating income |  |  |  |  |  |  |  |  |  | 5,284 |
Interest and other loss, net |  |  |  |  |  |  |  |  |  | (13) |
Interest expense |  |  |  |  |  |  |  |  |  | (26) |
Foreign exchange gains, net |  |  |  |  |  |  |  |  |  | 2,654 |
Income from operations before provision for income taxes |  |  |  |  |  |  |  |  |  | $ | 7,899 |
Nine Months Ended September 30, 2025 |  | Asia |  | Europe |  | North America |  | Latin America and Other |  | Total
Net sales |  | $ | 166,042 |  |  | $ | 67,962 |  |  | $ | 106,219 |  |  | $ | 16,114 |  |  | $ | 356,337 |
Cost of sales |  | 36,538 |  |  | 20,000 |  |  | 35,817 |  |  | 6,037 |  |  |
Volume incentives |  | 54,666 |  |  | 27,238 |  |  | 21,853 |  |  | 4,795 |  |  |
Selling, general and administrative (1) |  | 43,085 |  |  | 14,498 |  |  | 26,627 |  |  | 4,259 |  |  |
Segment operating income |  | $ | 31,753 |  |  | $ | 6,226 |  |  | $ | 21,922 |  |  | $ | 1,023 |  |  | $ | 60,924 |
Unallocated corporate selling, general and administrative expense |  |  |  |  |  |  |  |  |  | (41,503) |
Operating income |  |  |  |  |  |  |  |  |  | 19,421 |
Interest and other income, net |  |  |  |  |  |  |  |  |  | 524 |
Interest expense |  |  |  |  |  |  |  |  |  | (71) |
Foreign exchange gains, net |  |  |  |  |  |  |  |  |  | 4,451 |
Income from operations before provision for income taxes |  |  |  |  |  |  |  |  |  | $ | 24,325 |
Nine Months Ended September 30, 2024 |  | Asia |  | Europe |  | North America |  | Latin America and Other |  | Total
Net sales |  | $ | 151,497 |  |  | $ | 63,513 |  |  | $ | 103,719 |  |  | $ | 17,430 |  |  | $ | 336,159 |
Cost of sales |  | 35,905 |  |  | 21,231 |  |  | 33,416 |  |  | 5,983 |  |  |
Volume incentives |  | 50,615 |  |  | 25,022 |  |  | 22,354 |  |  | 5,793 |  |  |
Selling, general and administrative (1) |  | 39,415 |  |  | 13,945 |  |  | 24,387 |  |  | 4,855 |  |  |
Segment operating income |  | $ | 25,562 |  |  | $ | 3,315 |  |  | $ | 23,562 |  |  | $ | 799 |  |  | $ | 53,238 |
Unallocated corporate selling, general and administrative expense |  |  |  |  |  |  |  |  |  | (37,693) |
Operating income |  |  |  |  |  |  |  |  |  | 15,545 |
Interest and other income, net |  |  |  |  |  |  |  |  |  | 462 |
Interest expense |  |  |  |  |  |  |  |  |  | (141) |
Foreign exchange gains, net |  |  |  |  |  |  |  |  |  | 1,111 |
Income from operations before provision for income taxes |  |  |  |  |  |  |  |  |  | $ | 16,977 |
_________________________________________ (1) Service fees in China totaled $4.6 million and $10.9 million for the three- and nine-month periods ended September 30, 2025, respectively, compared to $3.5 million and $10.4 million for the three- and nine-month periods ended September 30, 2024. These service fees are included in selling, general and administrative expenses. The table below reflects sales based upon the sales location where they occurred. From an individual country/region perspective, the United States, Taiwan, Japan and South Korea comprise 10 percent or more of consolidated net sales for the three- and nine-month periods ended September 30, 2025 and 2024, as follows (dollar amounts in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Net sales: |  |  |  |  |  |  |
United States | $ | 33,721 |  |  | $ | 30,973 |  |  | $ | 98,687 |  |  | $ | 95,609 |
Taiwan | 18,854 |  |  | 18,389 |  |  | 53,446 |  |  | 50,489 |
Japan | 17,704 |  |  | 13,287 |  |  | 41,911 |  |  | 32,144 |
South Korea | 15,199 |  |  | 13,894 |  |  | 38,516 |  |  | 38,964 |
Other | 42,861 |  |  | 38,072 |  |  | 123,777 |  |  | 118,953 |
Total net sales | $ | 128,339 |  |  | $ | 114,615 |  |  | $ | 356,337 |  |  | $ | 336,159 |
Net sales generated by each product line for the three and nine months ended September 30, 2025 and 2024, are as follows (dollar amounts in thousands):
Three Months Ended September 30, 2025 |  | Asia |  | Europe |  | North America |  | Latin America and Other |  | Total
General health |  | $ | 24,817 |  | $ | 9,267 |  | $ | 16,231 |  | $ | 1,571 |  | $ | 51,886
Immune |  | 4,456 |  | 2,046 |  | 3,778 |  | 455 |  | 10,735
Cardiovascular |  | 15,935 |  | 2,600 |  | 4,036 |  | 394 |  | 22,965
Digestive |  | 13,657 |  | 5,788 |  | 9,411 |  | 2,514 |  | 31,370
Personal care |  | 2,365 |  | 1,481 |  | 1,795 |  | 206 |  | 5,847
Weight management |  | 3,495 |  | 925 |  | 973 |  | 143 |  | 5,536
Total net sales by segment |  | $ | 64,725 |  | $ | 22,107 |  | $ | 36,224 |  | $ | 5,283 |  | $ | 128,339
Three Months Ended September 30, 2024 |  | Asia |  | Europe |  | North America |  | Latin America and Other |  | Total
General health |  | $ | 22,572 |  | $ | 9,194 |  | $ | 15,259 |  | $ | 1,753 |  | $ | 48,778
Immune |  | 2,504 |  | 1,685 |  | 3,690 |  | 589 |  | 8,468
Cardiovascular |  | 14,556 |  | 2,997 |  | 3,630 |  | 448 |  | 21,631
Digestive |  | 10,905 |  | 3,675 |  | 8,583 |  | 2,846 |  | 26,009
Personal care |  | 1,175 |  | 765 |  | 1,512 |  | 309 |  | 3,761
Weight management |  | 3,581 |  | 1,299 |  | 957 |  | 131 |  | 5,968
Total net sales by segment |  | $ | 55,293 |  | $ | 19,615 |  | $ | 33,631 |  | $ | 6,076 |  | $ | 114,615
Nine Months Ended September 30, 2025 |  | Asia |  | Europe |  | North America |  | Latin America and Other |  | Total
General health |  | $ | 63,470 |  | $ | 29,370 |  | $ | 47,535 |  | $ | 4,811 |  | $ | 145,186
Immune |  | 11,311 |  | 6,474 |  | 11,887 |  | 1,424 |  | 31,096
Cardiovascular |  | 42,468 |  | 7,804 |  | 11,449 |  | 1,217 |  | 62,938
Digestive |  | 33,825 |  | 17,790 |  | 27,596 |  | 7,599 |  | 86,810
Personal care |  | 5,671 |  | 4,427 |  | 4,907 |  | 695 |  | 15,700
Weight management |  | 9,297 |  | 2,097 |  | 2,845 |  | 368 |  | 14,607
Total net sales by segment |  | $ | 166,042 |  | $ | 67,962 |  | $ | 106,219 |  | $ | 16,114 |  | $ | 356,337
Nine Months Ended September 30, 2024 |  | Asia |  | Europe |  | North America |  | Latin America and Other |  | Total
General health |  | $ | 57,697 |  | $ | 28,530 |  | $ | 46,698 |  | $ | 4,887 |  | $ | 137,812
Immune |  | 6,437 |  | 6,223 |  | 11,675 |  | 1,906 |  | 26,241
Cardiovascular |  | 42,155 |  | 7,712 |  | 11,371 |  | 1,331 |  | 62,569
Digestive |  | 27,201 |  | 15,535 |  | 26,306 |  | 8,083 |  | 77,125
Personal care |  | 3,511 |  | 3,178 |  | 4,665 |  | 854 |  | 12,208
Weight management |  | 14,496 |  | 2,335 |  | 3,004 |  | 369 |  | 20,204
Total net sales by segment |  | $ | 151,497 |  | $ | 63,513 |  | $ | 103,719 |  | $ | 17,430 |  | $ | 336,159
Depreciation and amortization by reportable business segment for the three and nine months ended September 30, 2025 and 2024, are as follows (dollar amounts in thousands):
|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  | 2025 |  | 2024 |  | 2025 |  | 2024
Depreciation and amortization: |  |  |  |  |  |  |  |
Asia |  | $ | 466 |  |  | $ | 496 |  |  | $ | 1,445 |  |  | $ | 1,509 |
Europe |  | 25 |  |  | 23 |  |  | 81 |  |  | 70 |
North America |  | 3,036 |  |  | 3,005 |  |  | 8,977 |  |  | 8,581 |
Latin America and Other |  | 12 |  |  | 12 |  |  | 35 |  |  | 35 |
Total depreciation and amortization |  | $ | 3,539 |  |  | $ | 3,536 |  |  | $ | 10,538 |  |  | $ | 10,195 |
From an individual country perspective, only the United States has material balances of consolidated property, plant and equipment as follows (dollar amounts in thousands):
|  | September 30, 2025 |  | December 31, 2024
Property, plant and equipment |  |  |  |
United States |  | $ | 29,815 |  |  | $ | 34,786 |
Other |  | 4,157 |  |  | 4,799 |
Total property, plant and equipment |  | $ | 33,972 |  |  | $ | 39,585 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration